Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

Background. Retreatment with pegylated interferon (peg-IFN) and ribavirin (RBV) results in poor sustained virological response (SVR) rates in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)–coinfected patients. There are limited data regarding the use of telaprevir plus peg-IFN/RBV in thi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2014-12, Vol.59 (12), p.1768-1776
Hauptverfasser:	Cotte, Laurent, Braun, Joséphine, Lascoux-Combe, Caroline, Vincent, Corine, Valantin, Marc-Antoine, Sogni, Philippe, Lacombe, Karine, Neau, Didier, Aumaitre, Hugues, Batisse, Dominique, de Truchis, Pierre, Gervais, Anne, Michelet, Christian, Morlat, Philippe, Vittecoq, Daniel, Rosa, Isabelle, Bertucci, Inga, Chevaliez, Stéphane, Aboulker, Jean-Pierre, Molina, Jean-Michel
Format:	Artikel
Sprache:	eng
Schlagworte:	AIDS Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretrovirals Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Clinical trials Coinfection - drug therapy Confidence intervals Dosage Female Genotypes Hepacivirus Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy HIV HIV infections HIV Infections - drug therapy HIV/AIDS Human immunodeficiency virus Human viral diseases Humans Infectious diseases Interferon Interferon-alpha - therapeutic use Interferons Life Sciences Male Medical sciences Middle Aged Oligopeptides - therapeutic use Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Prescription drugs Recombinant Proteins - therapeutic use Ribavirin - therapeutic use RNA Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral hepatitis Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!